US 11,970,722 B2
Engineered acid alpha-glucosidase variants
William Casey Hallows, San Francisco, CA (US); Rachel Cathleen Botham, Burlingame, CA (US); Yu Zhu, Newark, CA (US); Chinping Chng, Menlo Park, CA (US); Nikki Dellas, San Carlos, CA (US); Gjalt W. Huisman, Redwood City, CA (US); Moulay Hicham Alaoui Ismaili, San Mateo, CA (US); David William Homan, San Ramon, CA (US); Adam P. Silverman, San Carlos, CA (US); Jonathan Vroom, South San Francisco, CA (US); and Jessica P. Lao, San Carlos, CA (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Dec. 18, 2020, as Appl. No. 17/126,647.
Claims priority of provisional application 62/951,625, filed on Dec. 20, 2019.
Prior Publication US 2021/0189365 A1, Jun. 24, 2021
Int. Cl. A61K 38/00 (2006.01); C12N 9/34 (2006.01)
CPC C12N 9/2428 (2013.01) [C12Y 302/01003 (2013.01); A61K 38/00 (2013.01)] 39 Claims
 
1. A recombinant acid alpha glucosidase comprising an amino acid sequence comprising at least at least 85% sequence identity to the sequence of residues 20 to 944 of SEQ ID NO: 2, wherein the amino acid sequence comprises at least a substitution S135Q/P, V913G/H/L/Q/R/W/E, P39Q/D/H, Q50V, or T266N, or a substitution at amino acid position 150, or combinations thereof, wherein the amino acid positions are relative to SEQ ID NO: 2.